MedTrace Logo

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT03414970 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 898

Last updated 2026-02-24

Study results available
· View outcomes & findings →

Summary

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Conditions

  • Ductal Breast Carcinoma
  • Invasive Breast Carcinoma
  • Lobular Breast Carcinoma
  • Medullary Breast Carcinoma
  • Stage II Breast Cancer
  • Stage IIA Breast Cancer
  • Stage IIB Breast Cancer
  • Stage IIIA Breast Cancer
  • Tubular Breast Carcinoma

Interventions

RADIATION

Radiation Therapy

Undergo RT

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated RT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Matthew Poppe, MD · Huntsman Cancer Hospital, University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2024-02-01
Completion
2035-08-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03414970 on ClinicalTrials.gov